InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by CHILDS JOHN W, Director. Officer active across 3 companies, notably Veradermics, Inc. Cumulatively, 8 reports have been published. Total volume traded: €10.9m. The latest transaction was disclosed on 4 March 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
US$824,14128,400 shares@ US$29.0191100.0% of flow
Common Shares
SEC:0001027035-26-000006·
Ideal exit: 29 Nov 2025 (T+270)
€824,14128,400 shares@ €29.01910.055% mcap50.0% of flow
Common Shares
SEC:0001027035-26-000006:0·
Ideal exit: 29 Nov 2025 (T+270)
US$4m294,117 shares@ US$14.40480.10% mcap100.0% of flow
Common Stock
SEC:0001027035-26-000004·
Ideal exit: 2 Nov 2026 (T+270)
€4m294,117 shares@ €14.40480.10% mcap50.0% of flow
Common Stock
SEC:0001027035-26-000004:0·
Ideal exit: 2 Nov 2026 (T+270)
€113,292212,500 shares@ €0.53310.0086% mcap21.6% of flow
Common Shares
SEC:0001562180-21-007139·
€113,292212,500 shares@ €0.53310.0086% mcap10.8% of flow
Common Shares
SEC:0001562180-21-007139:0·
€411,7793,890 shares@ €105.85570.031% mcap78.4% of flow
Common Shares
SEC:0001562180-21-006983·
Ideal exit: 7 Aug 2022 (T+270)
€411,7793,890 shares@ €105.85570.031% mcap39.2% of flow
Common Shares
SEC:0001562180-21-006983:0·
Ideal exit: 7 Aug 2022 (T+270)
8 of 8 declarations
About CHILDS JOHN W
John W. Childs is a Board Member at Veradermics, Inc., Biohaven Ltd., and Biohaven Pharmaceutical Holding Co Ltd. He contributes to the governance of all three companies, bringing his expertise in management and strategy. His commitment to innovation is essential for long-term success.
